Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey.

ABSTRACT: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk factors do not take the tumor immune microenvironment into account. Consideration of the Immunoscore, which measures the host immune response at the tumor site, may assist clinicians in reducing adjuvant chemotherapy use in patients who are unlikely to benefit from it. This study sought to determine the potential clinical utility of the Immunoscore, via its effect on medical oncologists' recommendations for management of patients with stage II colon cancer. De-identified vignettes of 10 patients with stage II colon cancer were presented to 25 practicing medical oncologists. Each participant completed surveys indicating recommendations for adjuvant chemotherapy and surveillance strategies. An educat

SUBMITTER: Kasi A 

PROVIDER: S-EPMC8582441 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature